UBS initiates Insmed (INSM +0.7%) at Buy with a $17.50 price target representing a 37% upside....

|By:, SA News Editor

UBS initiates Insmed (INSM +0.7%) at Buy with a $17.50 price target representing a 37% upside. Arikace "has a solid chance of success in its primary indication of cystic fibrosis," analyst Matthew Harrison says, adding that the "underappreciated" non-tuberculous mycobacteria opportunity could be another growth catalyst going forward. (Previous: Arikace's NTM indication possibly more compelling than CF opportunity)